ArticleBreast cancer research and treatment2019
Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients
A View of Perceived Symptoms Associated with Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast Cancer
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Effects of an exercise program on chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer individuals receiving taxanes: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing.Breast cancer research and treatment · 2023Trial
- Longitudinal Changes in Somatosensory Function and Their Association with Pain Trajectory Groups in a Portuguese Cancer Center Cohort.Biomedicines · 2026Article
- Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies.Journal of gynecologic oncology · 2026Article
- Transcriptomic Modulation of Inflammasome-Related Genes Following Metformin Administration in Breast Cancer Patients with Paclitaxel-Induced Neuropathy.Clinical pharmacology : advances and applications · 2026Article
- Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol.Future science OA · 2025Article
- Single-nucleus rna sequencing identifies universal camk1d upregulation and dysregulated c-ltmr subtypes as key drivers of paclitaxel-induced neuropathy.Cell biology and toxicology · 2025Article
- Tolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment.Breast cancer research and treatment · 2025Article
- The Use of Nerve Conduction Study to Evaluate the Effects of Frozen Sock Treatment on Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Prospective Clinical Trial.Journal of clinical medicine · 2025Article
- Effects of taxane-induced peripheral neuropathy on hand dexterity impairment: evaluation of quantitative and subjective assessments.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Acetyl-L-carnitine for the prevention of taxane-induced neuropathy in patients with breast cancer: a systematic review and meta-analysis.Research in pharmaceutical sciences · 2023Review
- Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device.Cancer reports (Hoboken, N.J.) · 2023Article
- Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Identifying breast cancer recurrence histories via patient-reported outcomes.Journal of cancer survivorship : research and practice · 2022Article
- Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer.BioMed research international · 2022Article
- Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.Oncology and therapy · 2021Review
- Prevalence and predictors of peripheral neuropathy after breast cancer treatment.Cancer medicine · 2021Article
- Acupuncture Relieved Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast Cancer: A Pilot Randomized Sham-Controlled Trial.Journal of clinical medicine · 2021Article
- Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Review
- The detrimental association between fear of falling and motor performance in older cancer patients with chemotherapy-induced peripheral neuropathy.Gait & posture · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeCIPN is a common, debilitating, and dose-limiting side effect of chemotherapy. Here, we describe characteristics of patients with CIPN using both patient-reported outcomes (PRO) and quantitative sensory testing (QST).
methodsBreast cancer survivors with persistent moderate to severe CIPN defined by a rating of 4 or greater on a 0-10 Numeric Rating Scale (NRS) from two ongoing clinical trials were included. PROs included the Neuropathic Pain Scale (NPS) and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx). QST included tactile and vibration detection threshold measurements. Data were analyzed using descriptive statistics and Spearman correlation coefficients.
results49 female patients with a mean age of 61 years were assessed; 63% were Caucasian. Mean NRS scores were 4.2, 5.7, and 4.3 on 0-10 scale for pain, numbness, and tingling, respectively. Mean NPS score was 41.0 on a 0-100 scale, and the mean FACT/GOG-Ntx score was 25.8 on a 0-44 scale. QST showed mild to moderate impairments in tactile and vibration perception. The FACT/GOG-Ntx subscale for numbness was negatively correlated with tactile and vibration thresholds in both hands and feet (both p < 0.05). NPS was positively correlated with tactile thresholds in the hands and feet (p < 0.05).
conclusionPatients with moderate to severe CIPN report moderate pain, numbness, and tingling, and exhibit reduced tactile and vibration perception on QST. Weak to moderate correlations were observed between PRO and QST. These data suggest that QST outcomes are associated with CIPN symptoms and may be useful in helping monitor and manage CIPN treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.